Liposomal anthracyclines for breast cancer: Overview

Oncologist

Volumn 8, Issue SUPPL. 2, 2003, Pages 1-2

  O'Shaughnessy, Joyce ^a,b  

^a Baylor Charles A Sammons Cancer C   (United States)

^b Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; DAUNORUBICIN; DOXORUBICIN;

ADVANCED CANCER; ALOPECIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; EDITORIAL; GROWTH INHIBITION; HUMAN; NAUSEA; PRIORITY JOURNAL; TUMOR GROWTH; VOMITING;

EID: 0141629826     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.8-suppl_2-1     Document Type: Editorial

References (15)

1. Winer EP, Morrow M, Osborne CK et al. Malignant tumors of the breast. In: DeVita VT, Hellman S, Rosenberg RA, eds. Cancer: Principles & Practice of Oncology, Sixth Edition. Philadelphia: Lippincott Williams & Wilkins, 2001:1651-1717.
2. Hortobagyi GN. Anthracyclines in the treatment of cancer: an overview. Drugs 1997;54(suppl 4):1-7.
3. Maluf FC, Spriggs D. Anthracyclines in the treatment of gynecologic malignancies. Gynecol Oncol 2002;85:18-31.
4. Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710-717.
5. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003;97:2869-2879.
6. Harris L, Batist G, Belt R et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002;94:25-36.
7. Wigler N, O'Brien M, Rosso R et al. Reduced cardiac toxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin (CAELYX™/Doxil) vs. doxorubicin for first-line treatment of metastatic breast cancer. Poster presented at the 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, Florida, May 18-21, 2002.
8. Rivera E. Liposomal anthracyclines in metastatic breast cancer: clinical update. The Oncologist 2003;8(suppl 2): 3-9.
9. Safra T. Cardiac safety of liposomal anthracyclines. The Oncologist 2003;8(suppl 2):17-24.
10. Campos S. Liposomal anthracyclines: adjuvant and neoadjuvant therapy for breast cancer. The Oncologist 2003;8(suppl 2):10-16.
11. Wolff AC. Liposomal anthracyclines and new treatment approaches for breast cancer. The Oncologist 2003;8(suppl 2):25-30.
12. Theodoulou M, Campos SM, Batist G et al. TLC D99 (D, Myocet) and Herceptin (H) is safe in advanced breast cancer (ABC): final cardiac safety and efficacy analysis. Proc Am Soc Clin Oncol 2002;21:55a.
13. Trigo J, Climent MA, Gil M et al. Cardiac safety and activity of a phase I study of 3-weekly Myocet in combination with weekly Herceptin and paclitaxel in HER2-positive (HER2+) locally advanced or metastatic breast cancer (LA/MBC). Proc Am Soc Clin Oncol 2002;21:61a.
14. Wolff AC, Bonetti M, Sparano JA et al. Cardiac safety of trastuzumab (H) in combination with pegylated liposomal doxorubicin (D) and docetaxel (T) in HER2-positive metastatic breast cancer: preliminary results of ECOG 3198. Poster presented at the 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois, May 31-June 3, 2003.
15. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.